Telomir (NASDAQ: TELO) posts new Telomir-1 preclinical data in triple-negative breast cancer

Rhea-AI Filing Summary

Telomir Pharmaceuticals, Inc. reported new preclinical in vitro results for its investigational compound Telomir-1 (Telomir-Zn) in human triple-negative breast cancer (TNBC) cell lines. Telomir-Zn showed near-complete tumor cell mortality at 72 hours in the MDA-MB-468 model and significant partial reductions in viable tumor cells in the HCC70 and MDA-MB-231 models.

The company also found that adding supplemental iron reduced Telomir-Zn–induced tumor cell mortality, which it interprets as supporting an iron-dependent mechanism consistent with previously disclosed intracellular metal-modulating activity. Additional TNBC lines (BT-549 and HCC1806) are under evaluation, and a TNBC mouse xenograft study is being prepared in a mammalian system.

Telomir referenced earlier zebrafish xenograft work where Telomir-Zn achieved statistically significant reductions in tumor growth and metastasis in select TNBC models. It reiterated that it is continuing IND-enabling activities and anticipates submitting an Investigational New Drug application in the first quarter of 2026, after previously completing GLP safety and toxicology studies in rats and dogs without treatment-related adverse toxicity.

Insights

Biotech and clinical development analyst

Preclinical TNBC data strengthen Telomir-1’s scientific story but remain early-stage.

The disclosure centers on Telomir-1 (Telomir-Zn) activity in triple-negative breast cancer cell models. Near-complete tumor cell mortality in MDA-MB-468 and significant partial reductions in HCC70 and MDA-MB-231 suggest the compound may act across distinct TNBC molecular subtypes in vitro.

The iron-rescue experiments, where supplemental iron attenuated Telomir-Zn–induced tumor cell mortality, support an iron-dependent mechanism aligned with the asset’s previously described intracellular metal-modulating activity. Prior zebrafish xenograft data showing statistically significant reductions in tumor growth and metastasis provide an additional non-mammalian in vivo signal.

The company notes ongoing evaluation in BT-549 and HCC1806 TNBC lines, preparation of a TNBC mouse xenograft study, and continued IND-enabling work. It anticipates submitting an IND in the first quarter of 2026, following GLP safety and toxicology studies in rats and dogs where no treatment-related adverse toxicity was observed. Future regulatory and clinical outcomes will determine how these preclinical findings translate in humans.

false 0001971532 0001971532 2026-02-17 2026-02-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 17, 2026

TELOMIR PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

Florida		001-41952		87-2606031
(State or Other Jurisdiction		(Commission		(IRS Employer
of Incorporation)		File Number)		Identification No.)

100 SE 2nd St, Suite 2000, #1009

Miami, Florida 33131

(Address of Principal Executive Offices)

Registrant’s telephone number, including area code: (786) 396-6723

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

	☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, no par value		TELO		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 – Other Events

Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models

Iron-rescue experiments confirm tumor cell mortality is mechanistically driven, not nonspecific cytotoxicity.

On February 17, 2026, Telomir Pharmaceuticals, Inc. (the “Company”) announced new preclinical in vitro data evaluating its investigational compound Telomir-1 (Telomir-Zn) in human triple-negative breast cancer (“TNBC”) cell lines.

The Company reported that Telomir-Zn reduced viable tumor cell counts across multiple human TNBC models representing biologically distinct molecular subtypes. Specifically:

	●	MDA-MB-468 (Basal-A / EGFR-high): Near-complete tumor cell mortality was observed at 72 hours at evaluated concentrations.
	●	HCC70 (Basal-like): A significant partial reduction in viable tumor cells was observed at 72 hours.
	●	MDA-MB-231 (Claudin-low / mesenchymal): A significant partial reduction in viable tumor cells was observed at 72 hours.

The Company further reported that the addition of supplemental iron attenuated Telomir-Zn–induced tumor cell mortality across completed models. The Company interprets these findings as supporting an iron-dependent mechanism consistent with previously disclosed intracellular metal-modulating activity.

Two additional TNBC cell lines, BT-549 (mesenchymal-like) and HCC1806 (basal-like), are currently under evaluation.

The Company also referenced prior zebrafish xenograft studies in which Telomir-Zn demonstrated statistically significant reductions in tumor growth and metastasis in select TNBC models.

The Company stated that it is completing additional TNBC subtype evaluations, preparing a TNBC mouse xenograft study in a mammalian system, and continuing IND-enabling activities. As previously disclosed, the Company anticipates submitting an Investigational New Drug (IND) application in the first quarter of 2026.

The Company has previously reported completed IND-enabling GLP safety and toxicology studies in rats and dogs, in which no treatment-related adverse toxicity was observed.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TELOMIR PHARMACEUTICALS, INC.
Dated: February 17, 2026	By:	/s/ Erez Aminov
	Name:	Erez Aminov
	Title:	Chief Executive Officer

FAQ

What did Telomir Pharmaceuticals (TELO) report about Telomir-1 in triple-negative breast cancer?

Telomir Pharmaceuticals reported new preclinical in vitro data showing Telomir-1 (Telomir-Zn) reduced viable tumor cells in multiple human triple-negative breast cancer lines, including near-complete mortality at 72 hours in the MDA-MB-468 model and significant partial reductions in HCC70 and MDA-MB-231 cell lines.

How does supplemental iron affect Telomir-1’s activity in TELO’s new data?

The company stated that adding supplemental iron attenuated Telomir-Zn–induced tumor cell mortality across completed models. It interprets this iron-rescue effect as supporting an iron-dependent mechanism, consistent with previously disclosed intracellular metal-modulating activity underlying Telomir-1’s observed effects in triple-negative breast cancer models.

Which triple-negative breast cancer cell lines did TELO test with Telomir-1?

Telomir evaluated Telomir-Zn in MDA-MB-468 (Basal-A / EGFR-high), HCC70 (basal-like), and MDA-MB-231 (claudin-low / mesenchymal) TNBC cell lines, observing near-complete tumor cell mortality in MDA-MB-468 and significant partial reductions in viable tumor cells in both HCC70 and MDA-MB-231 after 72 hours of treatment.

What prior in vivo data on Telomir-1 did Telomir Pharmaceuticals highlight?

The company referenced earlier zebrafish xenograft studies where Telomir-Zn produced statistically significant reductions in tumor growth and metastasis in select triple-negative breast cancer models. These studies provide in vivo support, complementing the newly reported in vitro TNBC cell line data described in the same disclosure.

What are the next planned studies for Telomir-1 according to TELO?

Telomir stated it is completing additional TNBC subtype evaluations, including BT-549 and HCC1806 cell lines, and preparing a TNBC mouse xenograft study in a mammalian system. These efforts accompany ongoing IND-enabling activities designed to support future clinical testing of Telomir-1.

When does Telomir Pharmaceuticals expect to submit an IND for Telomir-1?

The company reaffirmed that, as previously disclosed, it anticipates submitting an Investigational New Drug (IND) application in the first quarter of 2026. This IND plan follows completed GLP safety and toxicology studies in rats and dogs, where no treatment-related adverse toxicity was reported.

What safety data for Telomir-1 has TELO reported so far?

Telomir has reported completed IND-enabling GLP safety and toxicology studies in rats and dogs for Telomir-1 (Telomir-Zn). In these studies the company observed no treatment-related adverse toxicity, supporting continued advancement toward an Investigational New Drug application for triple-negative breast cancer indications.

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 3.0 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB